Drug Trial Radar · NCT06075030
A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
Dec 2027
Primary completion
Dec 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Kind Pharmaceuticals LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of AND017 after 6 weeks of treatment in patients with cancer-related anemia who are receiving chemotherapy.
Conditions
- Chemotherapy Induced Anemia
Interventions
AND017Drug
Oral administration of AND017 capsules three times per week
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of responding patientTime frame: From baseline to Week 6 or End of Treatment visit
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.